Takeda Zasocitinib Gets FDA Priority Review for Psoriasis
Osaka, Japan & Cambridge, Massachusetts, U.S., September 14, 2026 Takeda has announced that the U.S. Food and Drug Administration...
DESTINY-Lung04
Advertisement
AstraZeneca and Daiichi Sankyo’s Enhertu Delivers 14.3-Month PFS in HER2-Mutant NSCLC
Seoul, South Korea, September 14, 2026 AstraZeneca and Daiichi Sankyo announced positive results from the Phase III DESTINY-Lung04 trial,...
Henlius and Sandoz Expand Global Strategic Biosimilar Effort
Shanghai, China, August 17, 2026 Shanghai Henlius Biotech, Inc. and Sandoz have entered into a strategic collaboration to expand...
Daiichi Sankyo and AstraZeneca Report Enhertu Phase 3 Win
Tokyo, Japan — August 17, 2026 Daiichi Sankyo and AstraZeneca announced positive topline results from the DESTINY-Lung04 Phase 3...
Advertisement
